{
    "eid": "2-s2.0-85089782033",
    "title": "Daratumumab rapidly reduces high-titre factor VIII inhibitors in haemophilia A patients during life-threatening haemorrhages",
    "cover-date": "2021-01-01",
    "subject-areas": [
        {
            "@_fa": "true",
            "$": "Hematology",
            "@code": "2720",
            "@abbrev": "MEDI"
        },
        {
            "@_fa": "true",
            "$": "Genetics (clinical)",
            "@code": "2716",
            "@abbrev": "MEDI"
        }
    ],
    "keywords": [],
    "authors": [
        "Chatphatai Moonla",
        "Noppacharn Uaprasert",
        "Phandee Watanaboonyongcharoen",
        "Mukmanee Meesanun",
        "Autcharaporn Sukperm",
        "Ratchaneekorn Jantasing",
        "Saruta Faknuam",
        "Chantiya Chanswangphuwana",
        "Chantana Polprasert",
        "Pimpayao Sodsai",
        "Benjaporn Akkawat",
        "Nattiya Hirankarn",
        "Udomsak Bunworasate",
        "Ponlapat Rojnuckarin"
    ],
    "citedby-count": 4,
    "ref-count": 14,
    "ref-list": [
        "The principal results of the International Immune Tolerance Study: a randomized dose comparison",
        "Rituximab for treatment of inhibitors in haemophilia A. A phase II study",
        "Inhibitor recurrence after immune tolerance induction: a multicenter retrospective cohort study",
        "Emicizumab prophylaxis in hemophilia A with inhibitors",
        "Daratumumab monotherapy in patients with treatment-refractory multiple myeloma (SIRIUS): an open-label, randomised, phase 2 trial",
        "Monoclonal antibodies targeting CD38 in hematological malignancies and beyond",
        "HemophiliaInhibitor Research Study Investigators. Validation of Nijmegen-Bethesda assay modifications to allow inhibitor measurement during replacement therapy and facilitate inhibitor surveillance",
        "Daratumumab depletes CD38+immune regulatory cells, promotes T-cell expansion, and skews T-cell repertoire in multiple myeloma",
        "Induction of immune tolerance in patients with hemophilia and antibodies to factor VIII by combined treatment with intravenous IgG, cyclophosphamide, and factor VIII",
        "The molecular mechanisms of immunomodulation and tolerance induction to factor VIII",
        "Effect of daratumumab on normal plasma cells, polyclonal immunoglobulin levels, and vaccination responses in extensively pre-treated multiple myeloma patients",
        "Maintenance of long-lived plasma cells and serological memory despite mature and memory B cell depletion during CD20 immunotherapy in mice",
        "Bortezomib delays the onset of factor VIII inhibitors in experimental hemophilia A, but fails to eliminate established anti-factor VIII IgG-producing cells",
        "Daratumumab in life-threatening autoimmune hemolytic anemia following hematopoietic stem cell transplantation"
    ],
    "affiliation": [
        {
            "affiliation-city": "Bangkok",
            "@id": "60022183",
            "affilname": "King Chulalongkorn Memorial Hospital",
            "@href": "https://api.elsevier.com/content/affiliation/affiliation_id/60022183",
            "affiliation-country": "Thailand"
        },
        {
            "affiliation-city": "Nakhon Pathom",
            "@id": "122914411",
            "affilname": "Nakhon Pathom Hospital",
            "@href": "https://api.elsevier.com/content/affiliation/affiliation_id/122914411",
            "affiliation-country": "Thailand"
        }
    ],
    "funding": [
        "King Chulalongkorn Memorial Hospital",
        "Janssen-Cilag",
        "Department of Laboratory Medicine",
        "Chulalongkorn University"
    ]
}